Marrone Bio Innovations MBII
$ 0.99
-5.9%
Quarterly report 2022-Q1
added 12-23-2023
Marrone Bio Innovations Balance Sheet 2011-2024 | MBII
Annual Balance Sheet Marrone Bio Innovations
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-10.6 M | -3.35 M | 6.51 M | -6.4 M | 63 M | 48.4 M | 38 M | -13 M | -12 M | 48.6 M | -1.41 M |
Long Term Debt |
7.69 M | 11.5 M | 11.8 M | 11.8 M | 62.2 M | 57.8 M | 57.6 M | 9.67 M | 12.3 M | 27.1 M | 293 K |
Long Term Debt Current |
1.38 M | 1.01 M | 913 K | - | - | 252 K | 267 K | 12.6 M | 157 K | - | - |
Total Non Current Liabilities |
- | 27.1 M | 28.1 M | 22.3 M | 65.6 M | 60.9 M | 60.9 M | 12.7 M | 15.4 M | 69.1 M | 40.7 M |
Total Current Liabilities |
45.2 M | 24.2 M | 21.1 M | 11.3 M | 22 M | 15.2 M | 12.9 M | 31.2 M | 11.7 M | - | - |
Total Liabilities |
57.4 M | 49.8 M | 49.2 M | 33.6 M | 87.6 M | 76.2 M | 73.8 M | 44 M | 27.1 M | 108 M | 43.9 M |
Deferred Revenue |
360 K | 374 K | 427 K | 438 K | 6.19 M | 5.65 M | 3.09 M | 4.56 M | 1.34 M | 324 K | 175 K |
Retained Earnings |
-357 M | -341 M | -321 M | -283 M | -266 M | -235 M | -204 M | -160 M | -105 M | -75.6 M | -34.7 M |
Total Assets |
87.1 M | 81.2 M | 72.7 M | 46.6 M | 36.9 M | 46 M | 71.8 M | 77.2 M | 68.9 M | 33.8 M | 9.82 M |
Cash and Cash Equivalents |
19.6 M | 15.8 M | 6.25 M | 18.2 M | 786 K | 9.61 M | 19.8 M | 35.3 M | 24.5 M | 10 M | 2.22 M |
Book Value |
29.7 M | 31.4 M | 23.6 M | 12.9 M | -50.7 M | -30.2 M | -2.02 M | 33.2 M | 41.8 M | -74.2 M | -34.1 M |
Total Shareholders Equity |
29.7 M | 31.4 M | 23.6 M | 12.9 M | -50.7 M | -30.2 M | -2.02 M | 33.2 M | 39 M | -74.2 M | -34.1 M |
All numbers in USD currency
Quarterly Balance Sheet Marrone Bio Innovations
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 7.59 M | 7.69 M | 11.2 M | 11.3 M | 11.4 M | 11.5 M | 11.4 M | 11.4 M | 11.6 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 9.67 M | 9.67 M | 9.67 M | 9.67 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.77 M | 7.77 M | 7.77 M | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 53.3 M | 57.4 M | 51.5 M | 50.9 M | 51.1 M | 49.8 M | 49 M | 52.3 M | 54.5 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 87.6 M | 87.6 M | 87.6 M | 87.6 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 44 M | 44 M | 44 M | 44 M | 30.9 M | 26.7 M | 27.1 M | 27.1 M | 68.4 M | 68.4 M | 68.4 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | 285 K | 360 K | 346 K | 388 K | 439 K | 374 K | 541 K | 534 K | 450 K | 427 K | 427 K | 427 K | 427 K | 438 K | 438 K | 438 K | 438 K | 6.19 M | 6.19 M | 6.19 M | 6.19 M | 5.65 M | 5.65 M | 5.65 M | 5.65 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 2.86 M | 2.86 M | 2.86 M | 2.86 M | 3.85 M | 2.54 M | 1.21 M | 1.21 M | 193 K | 324 K | 324 K | - | - | - | - | - |
Retained Earnings |
- | - | - | -365 M | -357 M | -352 M | -347 M | -344 M | -341 M | -337 M | -331 M | -328 M | -321 M | -321 M | -321 M | -321 M | -283 M | -283 M | -283 M | -283 M | -266 M | -266 M | -266 M | -266 M | -235 M | -235 M | -235 M | -235 M | -204 M | -204 M | -204 M | -204 M | -160 M | -160 M | -160 M | -160 M | -108 M | -96.2 M | -105 M | -105 M | -75.6 M | -75.6 M | -75.6 M | - | - | - | - | - |
Total Assets |
- | - | - | 76.2 M | 87.1 M | 82.1 M | 85.6 M | 86.5 M | 81.2 M | 72.1 M | 78.4 M | 79.4 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 46.6 M | 46.6 M | 46.6 M | 46.6 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M | 46 M | 46 M | 46 M | 46 M | 71.2 M | 71.2 M | 71.2 M | 71.2 M | 77.2 M | 77.2 M | 77.2 M | 77.2 M | 69.9 M | 76.4 M | 68.9 M | 68.9 M | 33.8 M | 33.8 M | 33.8 M | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 9.36 M | 19.6 M | 15 M | 17.5 M | 18.9 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 786 K | 786 K | 786 K | 786 K | 9.61 M | 9.61 M | 9.61 M | 9.61 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 24.5 M | 40.8 M | 24.5 M | 24.5 M | 10 M | 10 M | 10 M | - | 2.22 M | - | - | - |
Book Value |
- | - | - | 22.9 M | 29.7 M | 30.6 M | 34.7 M | 35.4 M | 31.4 M | 23.1 M | 26.1 M | 24.9 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | -50.7 M | -50.7 M | -50.7 M | -50.7 M | -30.2 M | -30.2 M | -30.2 M | -30.2 M | -2.02 M | -2.02 M | -2.02 M | -2.02 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 39 M | 49.8 M | 41.8 M | 41.8 M | -34.6 M | -34.6 M | -34.6 M | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 22.9 M | 29.7 M | 30.6 M | 34.7 M | 35.4 M | 31.4 M | 23.1 M | 26.1 M | 24.9 M | 23.6 M | 24.6 M | 3.5 M | 9.58 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | -50.7 M | -50.7 M | -50.7 M | -50.7 M | -30.2 M | -30.2 M | -30.2 M | -30.2 M | -2.02 M | -2.02 M | -2.02 M | -2.02 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 39 M | 49.8 M | 41.8 M | 41.8 M | -74.2 M | -74.2 M | -74.2 M | - | -34.1 M | - | - | - |
All numbers in USD currency